Bio Green Med Solution, Inc. — 2019 Q1 10-Q Summary
Filing identity discrepancy: The supplied filing is for Cyclacel Pharmaceuticals, Inc., not Bio Green Med Solution, Inc. The summary below reflects the filing text provided and should not be attributed to Bio Green without verification.
Business context and reporting period
This unaudited Form 10-Q covers the three months ended March 31, 2019, with comparisons to the three months ended March 31, 2018. Cyclacel is a clinical-stage biopharmaceutical company developing cancer therapies; it reported no revenue in either period.
Key programs include CYC065, a CDK inhibitor in clinical development; sapacitabine combinations, including studies involving seliciclib or olaparib; and CYC140, a PLK1 inhibitor in a first-in-human study. The company also reported discussions with regulatory authorities regarding its SEAMLESS AML study.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $0.798 million | $1.012 million |
| General and administrative expense | $1.364 million | $1.192 million |
| Total operating expenses / operating loss | $2.162 million / $(2.162) million | $2.204 million / $(2.204) million |
| Net loss | $(1.349) million | $(1.842) million |
| Net loss applicable to common stockholders | $(1.399) million | $(1.892) million |
| Basic and diluted loss per share | $(0.12) | $(0.14) |
| Net cash used in operating activities | $(2.139) million | $(3.684) million |
At March 31, 2019, cash and cash equivalents were $17.934 million; working capital was $17.637 million; and total assets were $21.510 million. Current liabilities were $2.487 million. The balance sheet reported a $1.468 million lease liability following adoption of lease accounting; it reported no conventional borrowings. The 6% convertible exchangeable preferred stock had an aggregate liquidation preference of approximately $4.007 million.
Cash increased $0.430 million during Q1 2019: operating cash use of $3.684 million was more than offset by $4.106 million of net common-stock issuance proceeds, $0.027 million of net investing inflow, and exchange-rate effects. The company sold 4,702,527 shares under its at-the-market offering during the quarter. Common shares outstanding increased from 12,497,447 at year-end 2018 to 17,199,974 at March 31, 2019.
Margins are not meaningful because the company had no revenue. Accumulated deficit was $351.639 million. The filing does not present a separate conventional debt balance.
Material changes versus the prior comparable period
- Net loss applicable to common stockholders increased by $0.493 million, while total operating expenses rose $0.042 million.
- R&D expense increased $0.214 million (27%), mainly reflecting progression of CYC065 clinical evaluation. G&A expense decreased $0.172 million (13%), primarily due to lower professional and consultancy costs.
- Other income fell from $0.631 million to $0.094 million, chiefly because the prior-year quarter included $0.566 million of royalties associated with an asset purchase agreement; no such income was recorded in Q1 2019.
- Operating cash use increased $1.545 million year over year, attributed mainly to working-capital changes and the higher net loss. Q1 2019 financing inflow was principally from the ATM share issuance.
- On January 1, 2019, the company adopted ASC 842 and recognized a right-of-use asset of $1.353 million and lease liability of $1.468 million at March 31, 2019. Prior periods were not recast, limiting balance-sheet comparability.
Outlook, commentary, risks and unusual items
- Management said the $17.9 million of cash at quarter-end, together with expected cash sources including R&D tax credits, was expected to fund planned operating and capital requirements through the end of 2020. The company said it lacked funds to complete development and commercialization of any candidate; funding beyond 2020 depends on raising additional capital.
- Management expected 2019 R&D spending to increase as CYC065 development progresses, while G&A spending was expected to decrease. The timing and scale of any SEAMLESS-related spending, including possible regulatory submissions, depend on discussions with regulators.
- The company warned that additional funding may not be available on acceptable terms or at all. A funding shortfall could lead to delays, reduced or discontinued trials or R&D, changes to its operating plan, or earlier partnering of programs on less favorable economics.
- Management reported that stratified and exploratory SEAMLESS analyses identified a potential patient population for the experimental arm; discussions with certain regulatory authorities had begun. The filing gives no assurance of regulatory acceptance or a registration pathway.
- A three-year MD Anderson collaboration provides for four studies with projected enrollment of up to 170 patients. MD Anderson bears patient costs; Cyclacel supplies investigational drugs and limited support, with certain payments due upon first commercial sale in studied indications.
- A quarterly cash dividend of $0.15 per share on the 6% preferred stock, declared March 7, 2019, was paid May 1, 2019. Management stated there were no material changes to the risk factors in its 2018 Form 10-K, and no legal proceedings were reported.
Important facts for investors to verify
- Confirm the registrant’s identity: the supplied text is a Cyclacel Pharmaceuticals filing despite the request metadata naming Bio Green Med Solution.
- Verify the projected cash runway through the end of 2020 against current spending, trial plans, tax-credit receipts and financing needs.
- Track regulatory feedback and next steps for SEAMLESS, as well as enrollment, safety and efficacy updates across CYC065, sapacitabine combinations and CYC140.
- Assess dilution and potential future financing: Q1 ATM sales added approximately 4.7 million shares; 7,490,500 warrants with a $2.00 exercise price were outstanding at quarter-end.
- Review lease commitments: remaining payments were reported at approximately $2.135 million, with a remaining lease term of about 6.5 years.
- Confirm whether royalty income under the legacy asset purchase agreement recurs; management said its timing and amount were not predictable.